Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Dacetuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Dacetuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Dacetuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Dacetuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Dacetuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Dacetuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Dacetuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Dacetuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Dacetuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Dacetuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Dacetuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Dacetuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Dacetuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Dacetuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Dacetuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Dacetuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Dacetuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Dacetuzumab. |
| Equol | Equol may increase the thrombogenic activities of Dacetuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Dacetuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Dacetuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Dacetuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Dacetuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Dacetuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Dacetuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Dacetuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Dacetuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Dacetuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Dacetuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Dacetuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Dacetuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dacetuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Dacetuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Dacetuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Dacetuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacetuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dacetuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Dacetuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dacetuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Dacetuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacetuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Dacetuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dacetuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacetuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacetuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacetuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dacetuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacetuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacetuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Dacetuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Dacetuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacetuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dacetuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dacetuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Dacetuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Dacetuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Dacetuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Dacetuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Dacetuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Dacetuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Dacetuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Dacetuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Dacetuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Dacetuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Dacetuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Dacetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Dacetuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Dacetuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Dacetuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Dacetuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Dacetuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Dacetuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Dacetuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Dacetuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Dacetuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Dacetuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Dacetuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Dacetuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Dacetuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Dacetuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Dacetuzumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Dacetuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Dacetuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Dacetuzumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Dacetuzumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Dacetuzumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Dacetuzumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dacetuzumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Dacetuzumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Dacetuzumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Dacetuzumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Dacetuzumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Dacetuzumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Dacetuzumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Dacetuzumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Dacetuzumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dacetuzumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Dacetuzumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Dacetuzumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Dacetuzumab. |